SAN FRANCISCO, Nov. 15, 2015 /PRNewswire/ -- Hepatocellular carcinoma (HCC) remains one of the cancers growing in frequency and mortality in the United States. Patients with hepatitis C virus (HCV) left untreated will often progress to cirrhosis and HCC. Direct acting antivirals (DAAs) now used to treat patients with HCV have achieved almost universal cure rates. However, the risk of HCC following cure is not clear. Researchers from Houston VA Medical Center and Baylor College of Medicine (Houston, TX) presented data at the annual meeting of the American Association for the Study of Liver Diseases on the risk of...
↧